nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
Ribrag, Vincent |
|
|
21 |
5 |
p. 309-317.e3 |
artikel |
2 |
Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
|
Rosenberg, Aaron S. |
|
|
21 |
5 |
p. 345-354.e4 |
artikel |
3 |
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
|
Shallis, Rory M. |
|
|
21 |
5 |
p. e483-e487 |
artikel |
4 |
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome
|
Morita, Kiyomi |
|
|
21 |
5 |
p. 338-344 |
artikel |
5 |
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy
|
Masarova, Lucia |
|
|
21 |
5 |
p. 318-327.e6 |
artikel |
6 |
Determination and Role of Epstein-Barr Virus in Patients With Lymphoproliferative Disorders
|
Colak, Meryem |
|
|
21 |
5 |
p. e488-e492 |
artikel |
7 |
Editorial Board
|
|
|
|
21 |
5 |
p. A4-A5 |
artikel |
8 |
Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia
|
Parrondo, Ricardo D. |
|
|
21 |
5 |
p. 355-360 |
artikel |
9 |
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
|
Lancman, Guido |
|
|
21 |
5 |
p. e470-e476 |
artikel |
10 |
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
Bazzell, Brian G. |
|
|
21 |
5 |
p. 295-308 |
artikel |
11 |
Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia
|
Phoompoung, Pakpoom |
|
|
21 |
5 |
p. e477-e482 |
artikel |
12 |
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment
|
Bellofiore, Claudia |
|
|
21 |
5 |
p. e456-e459 |
artikel |
13 |
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
|
Gómez García, Lara Maria |
|
|
21 |
5 |
p. 328-337.e1 |
artikel |
14 |
Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria
|
Fairchild, Andrew |
|
|
21 |
5 |
p. e464-e469 |
artikel |
15 |
Retrospective Analysis of the Impact of Adverse Event–Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies
|
Ma, Shuo |
|
|
21 |
5 |
p. e432-e448 |
artikel |
16 |
Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis
|
Hughes, David M. |
|
|
21 |
5 |
p. e460-e463 |
artikel |
17 |
Table of Contents
|
|
|
|
21 |
5 |
p. A6-A8, A10 |
artikel |
18 |
Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia
|
Rausch, Johanna |
|
|
21 |
5 |
p. e429-e431 |
artikel |
19 |
Treatment of Acute Leukemia During COVID-19: Focused Review of Evidence
|
Singh, Suvir |
|
|
21 |
5 |
p. 289-294 |
artikel |
20 |
Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis
|
Kumar, Vivek |
|
|
21 |
5 |
p. e449-e455 |
artikel |